Giovanni Almanzar (Würzburg / DE), Felix Baum (Würzburg / DE), Marie Steimer (Würzburg / DE), Lydia Jahn (Würzburg / DE), Sonja Hick (Würzburg / DE), Alexander Ess (Würzburg / DE), Christoph Rack (Würzburg / DE), Igor Turin (Würzburg / DE), Arne Schäfer (Würzburg / DE), Panagiota Arampatzi (Würzburg / DE), Thorsten Bischler (Würzburg / DE), Tom Gräfenhan (Würzburg / DE), Florian Erhard (Würzburg / DE), Thomas Hennig (Würzburg / DE), Lars Dölken (Würzburg / DE), Martin Feuchtenberger (Burghausen / DE), Marc Schmalzing (Würzburg / DE), Martina Prelog (Würzburg / DE)
Background: Janus-Kinase-inhibitors (JAKi) have been approved for several indications in autoimmune diseases. Clinical studies showed that non-selective JAKi (ns-JAKi) are associated with an increased risk of herpes zoster (HZ) by reactivation of varicella-zoster-virus (VZV), whereas selective JAK-1 inhibitors (JAK-1i) have a lower risk for HZ.
Goals: In order to understand the molecular mechanisms behind the different HZ risk between ns-JAK und JAK-1i, the study aims to analyze transcriptome patterns and VZV-specific cellular responses induced by administration of JAKi in vitro on lymphocytes obtained from patients with rheumatoid arthritis (RA) and healthy controls (HC).
Methods: Lymphocytes were stimulated by VZV-antigens in vitro under different concentrations with JAK-1i or ns-JAKi. ELISpot and immune-phenotyping by flow-cytometry were performed to screen for cellular reactivity. mRNA sequencing techniques were used for transcriptome analysis. Western-blot-analysis was performed to determine the phosphorylated signal-transducer-and-activator-of-transcription-(STAT) proteins to estimate functional JAK activity.
Results: JAKi-treated lymphocytes showed significantly lower spot-forming-units (SFU) in a concentration-dependent manner compared to untreated controls and a reduced expression of activation markers (CD69). Relative intensity of phosphorylated STAT1 (pSTAT1) was reduced by 81% by JAK-1i and by 94% by ns-JAKi using plasma-concentration-equivalent doses. JAKi-untreated VZV-stimulated conditions induced expression of STAT1 2.4-fold, STAT2 2.8-fold, STAT3 1.2-fold and STAT4 1.7-fold. Interferon-response-factor-7 (IRF7) was induced 3.6-fold. After treatment with JAK-1i, STAT1 was still induced 1.5-fold, but significantly reduced by 82% by ns-JAKi.
Summary: The data demonstrated that the impact on VZV-specific cellular responses was significantly higher in ns-JAKi-treated than in JAK-1i-treated lymphocytes. This may result in less severe impairment of VZV-induced STAT-signaling by selective JAK-1i compared to ns-JAKi and may explain the lower HZ incidence in JAK-1i compared to ns-JAKi-treated patients.
We use cookies on our website. Cookies are small (text) files that are created and stored on your device (e.g., smartphone, notebook, tablet, PC). Some of these cookies are technically necessary to operate the website, other cookies are used to extend the functionality of the website or for marketing purposes. Apart from the technically necessary cookies, you are free to allow or not allow cookies when visiting our website.